PD-1 Resistant Head And Neck Cancer Global Market Report 2025

Description

PD-1 resistant head and neck cancer refers to head and neck squamous cell carcinomas (HNSCCs) that do not respond to therapies aimed at targeting the programmed death-1 (PD-1) pathway. PD-1 is an immune checkpoint protein that, when blocked, can boost the body's immune system to fight cancer cells. However, some HNSCCs develop resistance to these therapies, either from the beginning (de novo resistance) or after initially responding (acquired resistance).

The primary treatments for PD-1-resistant head and neck cancer include chemotherapy, radiation therapy, surgery, and targeted therapy. Chemotherapy involves using drugs to destroy cancer cells or prevent their growth. These drugs can be given orally or intravenously and work by targeting rapidly dividing cells, including cancer cells. Chemotherapy is often combined with other treatments to increase its effectiveness. Treatment is applied at various stages, such as early stage, locally advanced stage, and metastatic stage. These therapies are used in the treatment of conditions such as squamous cell carcinoma, adenocarcinoma, nasopharyngeal carcinoma, and throat cancer, with end-users including hospitals, cancer research centers, and clinics.

The PD-1-resistant head and neck cancer market research report is one of a series of new reports from The Business Research Company that provides PD-1-resistant head and neck cancer market statistics, including PD-1-resistant head and neck cancer industry global market size, regional shares, competitors with a PD-1-resistant head and neck cancer market share, detailed PD-1-resistant head and neck cancer market segments, market trends and opportunities, and any further data you may need to thrive in the PD-1-resistant head and neck cancer industry. This PD-1-resistant head and neck cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The PD-1 resistant head and neck cancer market size has grown rapidly in recent years. It will grow from $1.28 billion in 2024 to $1.43 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth observed during the historic period can be attributed to several factors, including a rise in prevalence, greater adoption of immunotherapy, an increase in clinical trial activities, growing resistance to PD-1 inhibitors, and a heightened focus on combination therapies.

The PD-1 resistant head and neck cancer market size is expected to see rapid growth in the next few years. It will grow to $2.20 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth projected for the forecast period can be attributed to several factors, such as an increase in biomarker research, the development of new therapies, a rise in personalized medicine approaches, growing investment in oncology R&D, and more regulatory approvals. Key trends during this period include the advancement of combination therapies, progress in precision oncology, the adoption of next-generation sequencing, enhanced research on the tumor microenvironment, and the use of AI-driven drug discovery.

The growth of the PD-1-resistant head and neck cancer market is expected to be driven by increasing awareness and early diagnosis. The growing recognition of cancer and improvements in screening programs, healthcare initiatives, and diagnostic technologies are contributing to earlier detection and treatment. Early detection of PD-1-resistant head and neck cancer allows for timely interventions with alternative therapies, leading to better treatment outcomes and higher survival rates. For example, in January 2025, The National Health Service (NHS) in the UK reported that 120,958 of the 206,038 common cancers diagnosed between September 2023 and August 2024 were detected at an early stage. This represents 58.7% of diagnoses, a 2.7 percentage point increase compared to pre-pandemic levels, equating to an estimated additional 7,000 patients diagnosed early. As a result, the rise in awareness and early diagnosis is propelling market growth for PD-1-resistant head and neck cancer.

Major companies are focusing on innovative approaches to overcome treatment resistance, such as personalized cancer therapies. These treatments are tailored to a patient's genetic profile, tumor characteristics, and immune response, offering more precise and effective care. For instance, in November 2024, CEL-SCI Corporation, a US-based biotechnology company, gained FDA approval to include the PD-L1 biomarker in a head and neck cancer study. The study, which will begin in early 2025, will focus on newly diagnosed patients with low PD-L1 expression and no lymph node involvement to assess the safety and effectiveness of Multikine (Leukocyte Interleukin, Injection). This follows positive results from a previous Phase 3 trial, marking an important step in personalized cancer treatment and offering new hope for better managing PD-1-resistant cancers.

In October 2024, Exelixis Inc., a US-based biotech company, entered into a partnership with Merck & Co. Inc. to advance cancer treatment. This collaboration aims to test combination therapies for head and neck cancer and renal cell carcinoma. The agreement includes trials of KEYTRUDA combined with Exelixis' therapy for head and neck cancer and WELIREG for renal cell carcinoma. As part of the deal, Merck will supply KEYTRUDA for Exelixis' Phase 3 STELLAR-305 trial, targeting PD-L1-positive HNSCC, while both companies will co-fund trials for renal cell carcinoma. The goal of this partnership is to enhance treatment options by combining immunotherapy with targeted therapy.

Major players in the PD-1 resistant head and neck cancer market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GSK plc, Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, Coherus BioSciences Inc., Akeso Biopharma, Rakuten Medical Inc., PDS Biotechnology Corporation, LARVOL, Nanobiotix, ALX Oncology Holdings Inc., RAPT Therapeutics Inc., and Immutep Limited.

North America was the largest region in the PD-1 resistant head and neck cancer market 2024. The regions covered in PD-1-resistant head and neck cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the PD-1-resistant head and neck cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The PD-1-resistant head and neck cancer market consists of revenues earned by entities by providing services such as diagnostic testing, combination therapies, genomic services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The PD-1-resistant head and neck cancer market also includes sales of diagnostic tests, imaging services, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

PD-1 Resistant Head And Neck Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pd-1 resistant head and neck cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pd-1 resistant head and neck cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pd-1 resistant head and neck cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment Type: Chemotherapy; Radiation Therapy; Surgery; Targeted Therapy
2) By Stage Of Cancer: Early Stage; Locally Advanced Stage; Metastatic Stage
3) By Application: Squamous Cell Carcinoma; Adenocarcinoma; Nasopharyngeal Carcinoma; Throat Cancer
4) By End User: Hospitals; Cancer Research Centers; Clinics
Subsegments:
1) By Chemotherapy: Platinum-Based Chemotherapy; Taxanes; Antimetabolites; Topoisomerase Inhibitors
2) By Radiation Therapy: Intensity-Modulated Radiation Therapy (IMRT); Stereotactic Body Radiation Therapy (SBRT); Proton Beam Therapy; Brachytherapy
3) By Surgery: Tumor Resection; Neck Dissection; Reconstructive Surgery; Laser Surgery
4) By Targeted Therapy: EGFR Inhibitors; Angiogenesis Inhibitors; Cyclin-Dependent Kinase Inhibitors; PI3K/AKT/mTOR Inhibitors
Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; Novartis AG; Bristol-Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r34656

1. Executive Summary

2. PD-1 Resistant Head And Neck Cancer Market Characteristics

3. PD-1 Resistant Head And Neck Cancer Market Trends And Strategies

4. PD-1 Resistant Head And Neck Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global PD-1 Resistant Head And Neck Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global PD-1 Resistant Head And Neck Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global PD-1 Resistant Head And Neck Cancer Market Growth Rate Analysis
5.4. Global PD-1 Resistant Head And Neck Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global PD-1 Resistant Head And Neck Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global PD-1 Resistant Head And Neck Cancer Total Addressable Market (TAM)

6. PD-1 Resistant Head And Neck Cancer Market Segmentation

6.1. Global PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Radiation Therapy
Surgery
Targeted Therapy
6.2. Global PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Early Stage
Locally Advanced Stage
Metastatic Stage
6.3. Global PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Squamous Cell Carcinoma
Adenocarcinoma
Nasopharyngeal Carcinoma
Throat Cancer
6.4. Global PD-1 Resistant Head And Neck Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Cancer Research Centers
Clinics
6.5. Global PD-1 Resistant Head And Neck Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Platinum-Based Chemotherapy
Taxanes
Antimetabolites
Topoisomerase Inhibitors
6.6. Global PD-1 Resistant Head And Neck Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intensity-Modulated Radiation Therapy (IMRT)
Stereotactic Body Radiation Therapy (SBRT)
Proton Beam Therapy
Brachytherapy
6.7. Global PD-1 Resistant Head And Neck Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tumor Resection
Neck Dissection
Reconstructive Surgery
Laser Surgery
6.8. Global PD-1 Resistant Head And Neck Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
EGFR Inhibitors
Angiogenesis Inhibitors
Cyclin-Dependent Kinase Inhibitors
PI3K/AKT/mTOR Inhibitors

7. PD-1 Resistant Head And Neck Cancer Market Regional And Country Analysis

7.1. Global PD-1 Resistant Head And Neck Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global PD-1 Resistant Head And Neck Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific PD-1 Resistant Head And Neck Cancer Market

8.1. Asia-Pacific PD-1 Resistant Head And Neck Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China PD-1 Resistant Head And Neck Cancer Market

9.1. China PD-1 Resistant Head And Neck Cancer Market Overview
9.2. China PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India PD-1 Resistant Head And Neck Cancer Market

10.1. India PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan PD-1 Resistant Head And Neck Cancer Market

11.1. Japan PD-1 Resistant Head And Neck Cancer Market Overview
11.2. Japan PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia PD-1 Resistant Head And Neck Cancer Market

12.1. Australia PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia PD-1 Resistant Head And Neck Cancer Market

13.1. Indonesia PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea PD-1 Resistant Head And Neck Cancer Market

14.1. South Korea PD-1 Resistant Head And Neck Cancer Market Overview
14.2. South Korea PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe PD-1 Resistant Head And Neck Cancer Market

15.1. Western Europe PD-1 Resistant Head And Neck Cancer Market Overview
15.2. Western Europe PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK PD-1 Resistant Head And Neck Cancer Market

16.1. UK PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany PD-1 Resistant Head And Neck Cancer Market

17.1. Germany PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France PD-1 Resistant Head And Neck Cancer Market

18.1. France PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy PD-1 Resistant Head And Neck Cancer Market

19.1. Italy PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain PD-1 Resistant Head And Neck Cancer Market

20.1. Spain PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe PD-1 Resistant Head And Neck Cancer Market

21.1. Eastern Europe PD-1 Resistant Head And Neck Cancer Market Overview
21.2. Eastern Europe PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia PD-1 Resistant Head And Neck Cancer Market

22.1. Russia PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America PD-1 Resistant Head And Neck Cancer Market

23.1. North America PD-1 Resistant Head And Neck Cancer Market Overview
23.2. North America PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA PD-1 Resistant Head And Neck Cancer Market

24.1. USA PD-1 Resistant Head And Neck Cancer Market Overview
24.2. USA PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada PD-1 Resistant Head And Neck Cancer Market

25.1. Canada PD-1 Resistant Head And Neck Cancer Market Overview
25.2. Canada PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America PD-1 Resistant Head And Neck Cancer Market

26.1. South America PD-1 Resistant Head And Neck Cancer Market Overview
26.2. South America PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil PD-1 Resistant Head And Neck Cancer Market

27.1. Brazil PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East PD-1 Resistant Head And Neck Cancer Market

28.1. Middle East PD-1 Resistant Head And Neck Cancer Market Overview
28.2. Middle East PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa PD-1 Resistant Head And Neck Cancer Market

29.1. Africa PD-1 Resistant Head And Neck Cancer Market Overview
29.2. Africa PD-1 Resistant Head And Neck Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa PD-1 Resistant Head And Neck Cancer Market, Segmentation By Stage of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa PD-1 Resistant Head And Neck Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. PD-1 Resistant Head And Neck Cancer Market Competitive Landscape And Company Profiles

30.1. PD-1 Resistant Head And Neck Cancer Market Competitive Landscape
30.2. PD-1 Resistant Head And Neck Cancer Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. PD-1 Resistant Head And Neck Cancer Market Other Major And Innovative Companies

31.1. AstraZeneca PLC
31.2. GSK plc
31.3. Amgen Inc.
31.4. Boehringer Ingelheim International GmbH
31.5. Regeneron Pharmaceuticals Inc.
31.6. Incyte Corporation
31.7. Coherus BioSciences Inc.
31.8. Akeso Biopharma
31.9. Rakuten Medical Inc.
31.10. PDS Biotechnology Corporation
31.11. LARVOL
31.12. Nanobiotix
31.13. ALX Oncology Holdings Inc.
31.14. RAPT Therapeutics Inc.
31.15. Immutep Limited

32. Global PD-1 Resistant Head And Neck Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The PD-1 Resistant Head And Neck Cancer Market

34. Recent Developments In The PD-1 Resistant Head And Neck Cancer Market

35. PD-1 Resistant Head And Neck Cancer Market High Potential Countries, Segments and Strategies

35.1 PD-1 Resistant Head And Neck Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 PD-1 Resistant Head And Neck Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 PD-1 Resistant Head And Neck Cancer Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer